1 Unprofitable Stock with Exciting Potential and 2 We Find Risky

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Unprofitable companies face an uphill battle, but not all are created equal. Luckily for you, StockStory is here to separate the promising ones from the weak. Keeping that in mind, here is one unprofitable company investing heavily to secure market share and two that may never reach the Promised Land.

Two Stocks to Sell:

Stitch Fix (SFIX)

Trailing 12-Month GAAP Operating Margin: -1.6%

One of the original subscription box companies, Stitch Fix (NASDAQ:SFIX) is an online personal styling and fashion service that curates personalized clothing selections for customers.

Why Is SFIX Risky?

1. Performance surrounding its active clients has lagged its peers

2. Earnings per share lagged its peers over the last five years as they only grew by 11.5% annually

3. Free cash flow margin is projected to show no improvement next year

Stitch Fix’s stock price of $2.51 implies a valuation ratio of 6.7x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why SFIX doesn’t pass our bar.

Gilead Sciences (GILD)

Trailing 12-Month GAAP Operating Margin: -8.2%

From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ:GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.

Why Does GILD Fall Short?

1. Annual sales growth of 2.7% over the last five years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand

2. Efficiency has decreased over the last five years as its adjusted operating margin fell by 34.2 percentage points

3. Earnings per share have contracted by 15.4% annually over the last five years, a headwind for returns as stock prices often echo long-term EPS performance

At $156.54 per share, Gilead Sciences trades at 17.1x forward P/E. Read our free research report to see why you should think twice about including GILD in your portfolio, it’s free.

One Stock to Watch:

GitLab (GTLB)

Trailing 12-Month GAAP Operating Margin: -8.5%

With its all-remote workforce pioneering a new approach to software development, GitLab (NASDAQ:GTLB) provides a single-application DevSecOps platform that helps development, operations, and security teams collaborate to build, secure, and deploy software faster.

Why Does GTLB Stand Out?